{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-101390","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2025-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.443166+00:00","generated_at":"2026-05-17T02:40:07.348378+00:00","sec_items":["1.01","2.06","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Novavax enters lease assignment and asset sales with AstraZeneca for $59.8M; expects Q3 non-cash charges of $125-127M","bullets":["Assignment fee $15M, parcel sale $20M, asset sale $24.8M; total $59.8M from AstraZeneca.","Non-cash impairment of $96-98M in Q3 2025 from these transactions, plus $29M from convertible note extinguishment.","Parcel sale closes Q4 2025; lease assignment and asset sale close Q1 2026.","Novavax pays base rent for Jan-Jun 2026 under lease assignment; AstraZeneca responsible thereafter.","Corporate headquarters relocated from 700 Quince Orchard Rd to 21 Firstfield Rd, Gaithersburg."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-101390","json":"https://secwatch.observer/filing/0001104659-25-101390.json","markdown":"https://secwatch.observer/filing/0001104659-25-101390.md","text":"https://secwatch.observer/filing/0001104659-25-101390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925101390/0001104659-25-101390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925101390/tm2529188d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:40:07.348378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5632e266cc68f3f8f58531c509363ebf7e908b40","claim":"NOVAVAX INC announced a impairment with charges of between $96 million and $98 million affecting 700 Quince Orchard Road, Gaithersburg, MD facility.","evidence_excerpt":"on October 17, 2025, the Company concluded that it expects to recognize an estimated non-cash impairment charge of between $96 million and $98 million in the third quarter of 2025, which includes the write off of the right-of-use asset, property and equipment, and intangibles, partially offset by a gain recognized on the sale of adjacent land under the Parcel Agreement.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925101390/0001104659-25-101390-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"impairment"},{"label":"Charge","value":"between $96 million and $98 million"},{"label":"Affected area","value":"700 Quince Orchard Road, Gaithersburg, MD facility"}],"fact_type":"restructuring_charge"},{"claim_id":"61e6fa134b399896b5d5adb5b333fcb8b9c1c6c2","claim":"NOVAVAX INC announced a impairment with charges of $29 million.","evidence_excerpt":"the Company expects to recognize a non-cash charge of $29 million during the third quarter of 2025 associated with the extinguishment of the 5.00% Convertible Senior Notes due 2027 and announced on August 27, 2025.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925101390/0001104659-25-101390-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"impairment"},{"label":"Charge","value":"$29 million"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}